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Corticobasal degeneration is an uncommon parkinsonian variant condition that is diagnosed mainly on clinical examination.
To facilitate the differential diagnosis of this disorder, we used metabolic brain imaging to characterize a specific network that
can be used to discriminate corticobasal degeneration from other atypical parkinsonian syndromes. Ten non-demented patients
(eight females/two males; age 73.9  5.7 years) underwent metabolic brain imaging with 18F-fluorodeoxyglucose positron emis-
sion tomography for atypical parkinsonism. These individuals were diagnosed clinically with probable corticobasal degeneration.
This diagnosis was confirmed in the three subjects who additionally underwent post-mortem examination. Ten age-matched
healthy subjects (five females/five males; age 71.7  6.7 years) served as controls for the imaging studies. Spatial covariance
analysis was applied to scan data from the combined group to identify a significant corticobasal degeneration-related metabolic
pattern that discriminated (P5 0.001) the patients from the healthy control group. This pattern was characterized by bilateral,
asymmetric metabolic reductions involving frontal and parietal cortex, thalamus, and caudate nucleus. These pattern-related
changes were greater in magnitude in the cerebral hemisphere opposite the more clinically affected body side. The presence of
this corticobasal degeneration-related metabolic topography was confirmed in two independent testing sets of patient and control
scans, with elevated pattern expression (P5 0.001) in both disease groups relative to corresponding normal values. We next
determined whether prospectively computed expression values for this pattern accurately discriminated corticobasal degeneration
from multiple system atrophy and progressive supranuclear palsy (the two most common atypical parkinsonian syndromes) on a
single case basis. Based upon this measure, corticobasal degeneration was successfully distinguished from multiple system
atrophy (P50.001) but not progressive supranuclear palsy, presumably because of the overlap (24%) that existed between
the corticobasal degeneration- and the progressive supranuclear palsy-related metabolic topographies. Nonetheless, excellent
discrimination between these disease entities was achieved by computing hemispheric asymmetry scores for the corticobasal
degeneration-related pattern on a prospective single scan basis. Indeed, a logistic algorithm based on the asymmetry scores
combined with separately computed expression values for a previously validated progressive supranuclear palsy-related pattern
provided excellent specificity (corticobasal degeneration: 92.7%; progressive supranuclear palsy: 94.1%) in classifying 58 testing
subjects. In conclusion, corticobasal degeneration is associated with a reproducible disease-related metabolic covariance pattern
that may help to distinguish this disorder from other atypical parkinsonian syndromes.
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Introduction
Parkinsonism is characterized by a combination of clinical features
that include tremor, bradykinesia, rigidity, and postural instability.
Idiopathic Parkinson’s disease is the most common cause of neu-
rodegenerative parkinsonism, whereas atypical parkinsonian syn-
dromes, also referred to as ‘Parkinson plus syndromes,’ encompass
several specific diseases with distinct pathology and prognosis,
including progressive supranuclear palsy (PSP), multiple system
atrophy (MSA), and corticobasal degeneration (CBD). Atypical
parkinsonian syndromes can represent as much as 15-20% of
parkinsonism seen in specialty practice (Fahn et al., 2004).
Diagnosis of Parkinson’s disease and atypical parkinsonism is
made based on clinical examination, relying on established con-
sensus criteria. Parkinson’s disease and the different atypical
parkinsonian syndromes can be differentiated by pathological
examination, but post-mortem studies demonstrate only a 76%
accuracy in the clinical diagnosis of Parkinson’s disease (Hughes
et al., 2002). Although this accuracy does increase with longer
follow-up evaluations by movement disorder specialists, it remains
significantly lower for atypical syndromes (Hughes et al., 2002).
Pathologically, CBD and PSP are classified as tauopathies with
significant overlap in motor and cognitive deficits (Sha et al.,
2006), distinct from the alpha-synuclein aggregates that charac-
terize Parkinson’s disease and MSA (Poston, 2010). Clinically, CBD
is characterized by asymmetric, levodopa non-responsive parkin-
sonism. The presentation typically includes progressive rigidity and
limb apraxia, in conjunction with limb dystonia, stimulus-sensitive
myoclonus, and/or cortical sensory loss (Boeve et al., 2003).
However, predominantly cognitive presentations are also seen
(Litvan et al., 1997; Mahapatra et al., 2004; Hu et al., 2009),
potentially confounding the diagnosis.
With this in mind, one important aim of neuroimaging is to
provide increased diagnostic accuracy, allowing for the selection
of appropriate treatment strategies and more accurate long-term
prognosis. Conventional neuroimaging such as MRI is of limited
value in the diagnosis of the different atypical parkinsonian syn-
dromes. Asymmetric atrophy of the premotor and parietal cortices
is suggestive but neither sensitive nor specific for CBD, particularly
at early disease stages (Mahapatra et al., 2004). As Parkinson’s
disease and atypical parkinsonian syndromes are both associated
with presynaptic nigrostriatal dopaminergic deficits, dopaminergic
imaging has been of limited use in the differential diagnosis of
these disorders (Vlaar et al., 2007).
In contrast, functional imaging techniques aimed at measuring
cerebral blood flow or metabolism have been used extensively to
identify disease-specific changes in local neural activity (Eidelberg,
2009). In the past several years, voxel-based spatial covariance
analysis has been successfully applied to 18F-fluorodeoxyglucose
(FDG) PET images to identify metabolic patterns relating to spe-
cific neurodegenerative diseases (Eidelberg, 2009). Using this ap-
proach, we have previously identified and validated patterns that
can discriminate Parkinson’s disease, MSA, and PSP not only from
healthy subjects but also from each other (Spetsieris et al., 2009;
Tang et al., 2010b; Niethammer and Eidelberg, 2012).
To date, we have not applied this network-based method to the
study of CBD, although metabolic asymmetries can readily be seen
in patients with this disorder (Eidelberg et al., 1991). In the pre-
sent study, we identified and validated a disease-specific metabolic
pattern that can separate patients with CBD from healthy controls,
and patients with other atypical parkinsonian syndromes.
Materials and methods
Subjects
Demographic data for the patient cohorts and the healthy control
groups are presented in Table 1. Patients were referred to the respect-
ive institution to aid in clinical diagnosis between January 1995 and
December 2006 (North Shore University Hospital, NY, USA), March
2009 and October 2010 (Stanford University, CA, USA), July 2008
and January 2011 (University of Freiburg, Freiburg, Germany), and
between January 1998 and December 2008 (University Medical
Centre Groningen, Groningen, The Netherlands). All patients had par-
kinsonian signs and were followed by movement disorder specialists at
each institution for at least 6 months after PET imaging. Inclusion
required a final clinical diagnosis of probable CBD, PSP, or MSA that
was supported by the clinical impression of the trained movement
disorder specialists, who evaluated the patients, chart review (M.N.,
K.L.P., E.H., L.H., K.L.L., S.H., F.A.) using published clinical criteria
(Litvan, 2003; Poston, 2010; Armstrong et al., 2013), and the absence
of dementia as well as structural brain abnormalities on MRI (i.e. mass
lesions, white matter changes, or ischaemia) that could have explained
the clinical findings. Diagnosis was confirmed pathologically (J.P.V.) in
10 patients (three CBD, three PSP, and four MSA). Scan data from
some of the patients have appeared previously as part of different
analyses (Tang et al., 2010b; Teune et al., 2010; Hellwig et al., 2012).
To identify a CBD-related metabolic covariance pattern (CBDRP),
we studied 10 patients (CBDNS: eight females/two males; age
73.9  5.7 years (mean  standard deviation [SD]); disease duration
3.5  1.5 years; Table 2) who met diagnostic criteria for probable
CBD, with limb asymmetry and apraxia on clinical examination and
without evidence of eye movement abnormalities. Three of 10 subjects
with CBD were pathologically confirmed cases. Eight of the patients
with CBD in this group and 10 age-matched normal control subjects
(NLNS: five females/five males; age 71.7  6.7 years) were scanned at
North Shore University Hospital; two patients with CBD were scanned
at Stanford University. Six of 10 patients with CBD had symptoms
predominately on the right, and four on the left.
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To validate the pattern, we studied independent testing cohorts of
atypical parkinsonian syndromes subjects who had uncertain diagnoses
at the time of FDG PET and were then followed clinically by move-
ment disorder specialists for at least 6 months until a final clinical
diagnosis was made. We studied 10 patients with CBD (CBDGR:
seven females/three males; age 68.9  9.3 years; disease duration
2.0  0.82 years) and 10 normal control subjects (NLGR: five
females/five males; age 65.0  10.1 years) who were scanned with
FDG PET at the University Medical Centre Groningen, The
Netherlands. We also measured CBDRP expression in an additional
testing cohort comprised of seven patients with CBD (CBDFR: age
65.8  6.0 years; disease duration 2.3  1.6 years) who were scanned
with FDG PET at the University of Freiburg, Germany. CBD patients in
both cohorts were scanned with an unverified diagnosis of atypical
parkinsonian syndromes, and only confirmed as CBD on clinical
follow-up (3.0  1.0 years for CBDGR and 1.0  0.6 years for
CBDFR) (Teune et al., 2010; Hellwig et al., 2012).
To examine pattern expression in other atypical parkinsonian dis-
orders, we studied a cohort comprised of patients clinically diagnosed
with PSP (PSPNS: n = 30; age 69.4  5.6 years; disease duration
2.7  1.2 years) or MSA (MSANS: n = 40; age 61.4  8.7 years; dis-
ease duration 3.9  2.2 years) who were scanned with FDG PET at
North Shore University Hospital. Among these patients, three cases
with PSP and four MSA cases were pathologically confirmed. We
also studied an additional atypical parkinsonian syndromes cohort
comprised of patients diagnosed with PSP (PSPFR: n = 21; age
70.5  7.6 years; disease duration 2.9  2.0 years) or MSA (MSAFR:
n = 12; age 65.1  7.2 years; disease duration 3.6  2.0 years) who
were scanned at the University of Freiburg. All of these patients had
uncertain diagnoses of atypical parkinsonian syndromes at the time of
imaging, and their final clinical diagnoses were made after clinical
follow-up (PSPNS: 1.9  1.1 years; PSPFR: 1.0  0.4 years; MSANS:
3.2  2.6 years; MSAFR: 0.8  0.3 years) (Tang et al., 2010b;
Hellwig et al., 2012).
Ethical permission for the procedures was obtained from the
Institutional Review Board at North Shore University Hospital and
Stanford University, and the local ethics committee at University of
Freiburg and the University Medical Centre Groningen. Written con-
sent was obtained at each institution from each subject following
detailed explanation of the scanning procedures.
PET
All subjects were scanned with FDG PET under resting conditions.
All anti-parkinsonian medications were withheld at least 12 h before
imaging. PET imaging was performed using a GE Advance tomograph
[4.0 mm, full-width at half-maximum (FWHM), North Shore University
Hospital], a GE PET/CT Discovery LS (5 mm FWHM, Stanford
University), a Siemens ECAT HR + PET scanner (4.1 mm FWHM,
University Medical Centre Groningen), or a Siemens ECAT EXACT
922/47 scanner (5.5 mm FWHM; University of Freiburg) as described
previously (Huang et al., 2007; Teune et al., 2010; Meyer et al.,
2011). Scans from each subject were realigned and spatially normal-
ized to a standard Talairach-based FDG PET template, and smoothed
with an isotropic Gaussian kernel (10 mm) in all directions to improve
the signal-to-noise ratio (Feigin et al., 2007; Huang et al., 2007). All
image processing was performed using Statistical Parametric Mapping
(SPM5) software (Wellcome Department of Cognitive Neurology,
London, UK) running in MATLAB (MathWorks).
Network analysis
CBDRP identification
To identify a specific metabolic pattern associated with CBD, we
applied a spatial covariance mapping algorithm (Eidelberg, 2009;
Niethammer and Eidelberg, 2012; Spetsieris et al., 2013) to the FDG
PET data from the 10 CBDNS patients and 10 NLNS subjects that
comprised the derivation set. This method is based on a principal com-
ponent analysis that can be used to identify specific disease-related
spatial covariance patterns with significantly greater expression
(denoted by higher subject scores) in patients than in control subjects.
A detailed description of this approach has appeared elsewhere
(Habeck and Stern, 2010; Spetsieris and Eidelberg, 2011). In brief,
principal component analysis was performed on scans from the
Table 1 Patient cohorts
Site Category n Age (years) Disease
duration (years)
North Shore University Hospital/Stanford University (NS) NL (NLNS) 10 71.7  6.7 n/a
CBD (CBDNS) 10 73.9  5.7 3.5  1.5
PSP (PSPNS) 30 69.4  5.6 2.7  1.2
MSA (MSANS) 40 61.4  8.7 3.9  2.2
University Medical Centre Groningen (GR) NL (NLGR) 10 65.0  10.1 n/a
CBD (CBDGR) 10 68.9  9.3 2.0  0.8
University of Freiburg (FR) CBD (CBDFR) 7 65.8  6.0 2.3  1.6
PSP (PSPFR) 21 70.5  7.6 2.9  2.0
MSA (MSAFR) 12 65.1  7.2 3.6  2.0
Table 2 Patient characteristics: derivation cohort (CBDNS)
Subject
No.
Gender Age
(years)
Disease
duration
(years)
Clinically
worse
side
Pathologically
confirmed
CBDRP
score
(z-scored)
1 F 74.5 3 Left Yes 5.02
2 F 61.9 1 Right Yes 5.59
3 M 81.0 3 Right Yes 12.01
4 F 78.2 2 Right No 5.26
5 F 73.2 5 Right No 6.41
6 F 77.6 6 Right No 8.04
7 F 76.0 3 Right No 4.07
8 F 72.5 6 Left No 5.50
9 F 68.2 1 Left No 8.14
10 M 79.2 5 Left No 6.75
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combined group of patients and normal controls (n = 20) using an
automated voxel-based routine (software freely available at http://
feinsteinneuroscience.org/imaging-software) in a common stereotaxic
space. The combination of principal component patterns that best
discriminated patients from controls in the derivation set was identified
using pre-specified subject score criteria (Spetsieris and Eidelberg,
2011). To delineate a specific CBD-related topography, we limited
the analysis to the set of principal components that in aggregate ac-
counted for the top 50% of subject  voxel variability, and for which
each individual principal component contributed at least 10% to the
total variance in the scan data. Region weights for the resulting dis-
ease-related topography (denoted by voxel loadings on the pattern)
were tested for reliability using bootstrap resampling (Habeck and
Stern, 2010). Coordinates were reported in the standard anatomical
space developed at the Montreal Neurological Institute. The cytoarchi-
tectonic localization of each reported network-related region was con-
firmed using the Talairach space utility available at http://www.ihb.
spb.ru/pet_lab/TSU/TSUMain.html. For pattern derivation, the scans
from the CBD patients with predominantly left-sided symptoms were
flipped so that all subjects had the left hemispheres of the brain as
their most affected side.
CBDRP validation
Following derivation, the CBDRP candidate network was validated by
computing its expression in patient and control testing data from the
CBDGR, CBDFR, and NLGR cohorts. The Freiburg data set did not in-
clude scans from healthy control subjects. As in the derivation set,
scans of patients with CBD with predominantly left-sided symptoms
in the testing cohorts were flipped so that the most affected hemi-
sphere was on the left side. Subject scores for the candidate CBDRP
identified in the derivation set were computed in the testing scans
using an automated voxel-based algorithm to quantify the expression
of known patterns on a prospective single scan basis (Spetsieris et al.,
2006, 2013; Eidelberg, 2009) and were compared across groups. In
addition, CBDRP expression values were computed in scans from the
testing cohorts with PSP (PSPNS and PSPFR) or MSA (MSANS and
MSAFR). The resulting subject scores were compared with values
from the corresponding CBD cohorts (CBDNS and CBDFR).
CBDRP asymmetry index
To obtain a quantitative measure of the pattern asymmetry in individ-
ual subjects, we generated a hemi-CBDRP from the left side (most
affected hemisphere) of the whole-brain pattern. For each subject,
hemi-CBDRP expression values were computed separately for the
two hemispheres (hemi-CBDRP was flipped to calculate the value for
the right hemisphere). The difference in hemispheric values was calcu-
lated and used as an asymmetry index of CBDRP expression. Values
from the diagnostically relevant patient groups (CBD and PSP) were
compared with each other and with measures from the healthy vol-
unteer group.
Differential diagnosis
In addition to assessing group differences in the expression of covari-
ance patterns relating to CBD and PSP in the testing populations, we
developed an automated logistic algorithm to discriminate between
these disorders at the individual patient level. To this end, we
extended the pattern-based classification strategy that we previously
developed to distinguish patients with Parkinson’s disease from MSA
and PSP (Tang et al., 2010b). A training sample was constructed using
scans from the 10 CBDNS subjects used for CBDRP derivation (age
73.9  5.7 years) and scans from 10 PSPNS patients (age 69.9  8.2
years) closely matched in age to their CBDNS counterpart subjects.
Logistic regression analysis was performed on the scan data from
this combined training sample to determine which of the three net-
work measures [i.e. CBDRP expression, CBDRP asymmetry index, and
PSP-related metabolic covariance pattern (PSPRP) expression] could,
singly or in combination, best differentiate between the two diseases.
The model with the best between-group discrimination was selected
based on the lowest Akaike information criterion value (Burnham and
Anderson, 2002).
For validation, this algorithm was used prospectively to classify each
of 58 independent subjects. This testing set was comprised of 17 CBD
(10 CBDGR and seven CBDFR) and 41 PSP patients (20 remaining
PSPNS and 21 PSPFR). For each subject, probability values for CBD
(PCBD) or PSP (PPSP) were computed using the original logistic equation
from the training sample and then compared to the optimal cut-off
probabilities for classifying a given subject as CBD or PSP (i.e. cut-
offCBD or cut-offPSP). The cut-off probability for each condition
was determined by identifying an inflection point on each receiver-
operating characteristic (ROC) curve corresponding to high specificity
and sensitivity (Tang et al., 2010b). Because in a clinical setting FDG
PET is used primarily as a confirmatory test rather than for screening,
high specificity (i.e. 490%) rather than high sensitivity was preferred
in determining a suitable inflection point for each curve and, corres-
pondingly, the cut-off probability for each disease. By comparing the
individual case probabilities (PCBD and PPSP) to the cut-off probabilities,
each subject was classified as CBD if PCBD4 cut-offCBD, PSP if
PPSP4 cut-offPSP, or as an indeterminate case if PCBD4 cut-offCBD
and PPSP4 cut-offPSP. We then calculated discriminative measures
(sensitivity, specificity, positive predictive value and negative predictive
value) for the CBD and PSP groups.
Statistical analysis
Because of the relatively small sample size of some groups (e.g. n = 7
in CBDFR), the non-normal distribution of the data in some groups,
and unequal sample sizes, non-parametric tests were used to compare
network measures between (Mann-Whitney U-tests) and among
(Kruskal-Wallis tests) the different groups. For all patients and control
subjects, individual pattern scores were standardized (z-scored) with
respect to the original NLNS group used in pattern derivation. Thus, for
each of these normal reference samples, mean pattern expression was
zero with an SD of one. Logistic regression analysis was performed in
SAS 9.2 (SAS Institute Inc.) and other statistical tests were performed
in SPSS 14.0 (SPSS Inc.). All tests were considered significant for
P5 0.05.
Results
Corticobasal degeneration-related
metabolic pattern
Spatial covariance analysis of the metabolic imaging data from the
derivation set revealed a significant CBDRP (principal component
1, accounting for 18.4% of the total subject  voxel variance of
the data). This pattern (Fig. 1A and Table 3) was characterized by
metabolic reductions in the primary motor (BA4), lateral premotor
(BA6), prefrontal (BA9) and parietal (BA40) cortical regions, cin-
gulate gyrus (BA24, BA31) and in the thalamus (mediodorsal,
ventrolateral and lateroposterior nuclei). The changes in these
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network regions were more pronounced in the left hemisphere
(i.e. opposite the more affected body side), although abnormal
changes were also present in the other hemisphere, albeit at
lower significant levels (not shown in Fig. 1A). Voxel weights on
CBDRP were stable in these regions (inverse coefficient of varia-
tion range = 2.22 to 2.26, P = 0.01; bootstrap estimation, 1000
iterations). In the derivation set, pattern expression values (Fig. 1B
and D) significantly separated the patients with CBD from the
healthy control subjects (P50.001; permutation test). The clin-
ical diagnosis of CBD was confirmed post-mortem in three of
10 subjects (Fig. 1B and Table 2) used to identify the
pattern. In each of the autopsied cases, subject scores were
Figure 1 Corticobasal degeneration-related pattern. (A) Corticobasal degeneration-related pattern (CBDRP) identified by spatial co-
variance analysis of FDG PET scans from a derivation cohort of 10 patients with CBD and 10 normal control (NL) subjects scanned at the
North Shore University Hospital (eight CBD and 10 control subjects) and Stanford University (two CBD subjects). This pattern was
characterized by metabolic reductions in the left frontal and parietal lobes, precentral gyrus, thalamus, and caudate head, associated with
increased metabolism in the left occipital lobe, left lingual gyrus, right occipital lobe and right inferior occipital gyrus. [The display
represents regions that contributed significantly to the network at Z = 2.33 (P5 0.01) and were demonstrated to be reliable (P = 0.01;
1000 iterations) by bootstrap resampling. Voxels with positive region weights (metabolic increases) are colour-coded red and those with
negative region weights (metabolic decreases) are colour-coded blue. Left hemisphere is labelled as ‘L’]. (B) In this derivation sample,
individual CBDRP expression significantly (P50.001, permutation test) separated the 10 patients with CBD (CBDNS; filled circles) from the
10 normal controls (NLNS; open circles). The three pathologically confirmed cases are indicated by black filled circles. One subject with CBD
also had undergone FDG PET 3 years before the scan included in the derivation sample. For this subject, CBDRP expression was 1.64 at the
initial scan, and was then increased to 5.50 3 years later when the same subject carried a diagnosis of CBD (open and filled triangles,
respectively). (C) Top: Cortico-subcortical micrograph of the precentral gyrus (BA4) from a section stained with AT8 antibodies directed
against phosphorylated tau. On general survey, the labelling was diffuse, blurring the cortico-subcortical demarcation. Inset: Strong
labelling was seen of neuropil threads, astrocytes, and scattered neurons. Bottom: Cortico-subcortical micrograph from the same specimen
showing AT8 staining in the inferior frontal gyrus (BA9). Inset: In contrast to BA4, the cortico-subcortical demarcation is discrete and the
tauopathic burden consists only of occasional astrocytic plaques and rare neuropil threads. Scale bars = 1.0 cm; inset = 15mm.
(D) Validation of CBDRP in two independent testing cohorts: CBDGR (10 patients with CBD and 10 age-matched normal controls scanned
at University Medical Centre Groningen) and CBDFR (seven patients with CBD scanned at the University of Freiburg). As in the derivation
CBDNS cohort (left; P50.001, Mann-Whitney test), pattern expression was significantly elevated in the CBDGR patients compared to the
NLGR controls (middle; P50.001). Likewise, pattern expression in CBDFR (right) was significantly elevated relative to both the NLNS
(P = 0.001) and NLGR (P50.001) groups. Indeed, average elevation of CBDRP expression was not different (P = 0.55, Kruskal-Wallis test)
between the derivation and the two validation CBD groups. Error bars represent SE. **P4 0.001, Mann-Whitney tests, compared to
normal control subjects (NL).
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45.0 SD (range 5.0–12.0) above the normal mean value. The
pathological representation of an autopsied case who had the
highest CBDRP score (12.01) is shown in Fig. 1C. Of note, one
of the CBD patients (Fig. 1B) had undergone FDG PET 3 years
before the scan used in pattern identification. At that time, the
clinical diagnosis was one of focal dystonia, without accompanying
parkinsonism or cortical sensory findings. In this subject, CBDRP
expression was 1.64 at the initial scan, but increased to 5.5
(Fig. 1B) after 3 years, by which time a clinical diagnosis of CBD
had been made.
Pattern validation
To validate the CBDRP, we prospectively computed the expression
of this pattern in an independent testing cohort comprised of
10 patients with CBD (CBDGR) and 10 age-matched normal con-
trol subjects (NLGR) scanned at University Medical Centre
Groningen. Subject scores for this pattern were computed on a
prospective single scan basis in each of testing scans using an
automated voxel-based algorithm that was blind to diagnostic cat-
egory (i.e. CBDGR or NLGR). In this testing sample (Fig. 1D) CBDRP
expression was also elevated (P50.001; Mann-Whitney test) in
the patients (CBDGR) relative to the healthy (NLGR) control sub-
jects. Of note, subject scores in both cohorts were standardized
with respect to CBDRP expression values from the healthy NLNS
subjects in the derivation sample. Nevertheless, the mean for the
prospectively computed NLGR values (0.24) was near the zero
mean (P = 0.36, Mann-Whitney test) that was set for the NLNS
(see ‘Materials and methods’ section).
Lastly, we computed CBDRP expression in an additional testing
cohort comprised of seven patients with CBD (CBDFR) scanned at
the University of Freiburg. Although no scans from healthy control
subjects were available at this site, subject scores for CBDFR
patients (Fig. 1D) were significantly elevated (P40.001,
Mann-Whitney test) relative to healthy NLNS and NLGR control
values. Indeed, the expression of this pattern in CBDFR patients
(CBDFR: 5.39  0.89) did not differ (P = 0.55; Kruskal-Wallis test)
from corresponding measurements in CBDNS and CBDGR patients
[CBDNS: 6.68  0.72 (derivation); CBDGR: 5.35  1.27].
CBDRP expression in other forms
of atypical parkinsonism
To determine the specificity of the pattern for CBD, we measured
its expression in other forms of atypical parkinsonian syndromes.
Specifically, we quantified CBDRP scores in 30 PSP patients
(PSPNS) and 40 MSA patients (MSANS) scanned at North Shore
University Hospital. The patients in the CBDNS group (Fig. 2) had
greater CBDRP expression than either the PSPNS (P50.05) or the
MSANS (P50.001; Mann-Whitney tests) groups. We also com-
puted CBDRP expression values in 21 patients with PSP and 12
with MSA scanned at the University of Freiburg, designated as
PSPFR and MSAFR, respectively. CBDRP expression (Fig. 2) was
also elevated in CBDFR compared with MSAFR. However, CBDRP
scores in the CBDFR patients did not differ (P = 0.96) from those
computed in their PSPFR counterparts. Moreover, PSPNS and PSPFR
subjects had greater CBDRP expression (P50.001; Mann-
Whitney tests) than NLNS or NLGR control values. Thus, while con-
firming the presence of abnormal increases in CBDRP expression in
Figure 2 CBDRP expression in atypical parkinsonian syn-
dromes. Left: CBDRP expression in 10 patients with CBD
(CBDNS), 30 patients with PSP (PSPNS) and 40 patients with MSA
(MSANS) scanned with FDG PET at the North Shore University
Hospital. The patients in the CBDNS group showed higher
CBDRP expression than both the PSPNS (P50.05; Mann-
Whitney test) and MSANS (P50.001) patient groups. Right:
CBDRP expression in independent groups of seven CBD
(CBDFR), 21 PSP (PSPFR) and 12 MSA (MSAFR) patients scanned
with FDG PET at the University of Freiburg. In these groups,
CBDRP expression was significantly elevated in the patients with
CBD compared with the patients with MSA (P50.001; Mann-
Whitney test), but was not different from the patients with PSP
(P = 0.96). In addition, both PSPNS and PSPFR patients showed
higher CBDRP expression (P50.001; Mann-Whitney test) than
the normal (NLNS) control subjects. Error bars represent SE.
**P40.001, Mann-Whitney tests, compared to normal control
subjects.
Table 3 Brain regions with significant contributions to the
CBD-related pattern
Brain region Coordinatesa Zmax
x y z
Network-related metabolic reductions (negative region weights)
Thalamus MD/VL/LP nuclei,
Left 2 22 2 3.50
Right 6 14 2 2.53
Left inferior parietal lobule, BA40 44 38 56 3.22
Left precentral gyrus, BA4/6 32 16 68 3.19
40 2 28 2.88
Left cingulate gyrus, BA31 10 24 40 2.89
Left inferior frontal gyrus, BA9 52 14 28 2.80
Left middle frontal gyrus, BA6 28 16 62 2.67
Left cingulate gyrus, BA24 8 8 40 2.66
Network-related metabolic increases (positive region weights)
Left lingual gyrus, BA18 26 70 4 3.20
Right inferior occipital gyrus, BA18 40 92 18 2.83
Right lingual gyrus, BA17 20 102 16 2.77
a Montreal Neurological Institute standard space.
MD = mediodorsal; VL = ventrolateral; LP = lateroposterior; BA = Brodmann area.
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multiple prospective CBD cohorts, the testing data also revealed
significant pattern elevations in PSP patients.
CBDRP asymmetry index and PSPRP
expression
We used the inherent asymmetries that characterize the CBDRP
topography to define a hemispheric pattern. The hemi-CBDRP
topography was defined by the left hemisphere of the original
whole-brain pattern. As the side opposite the more affected
limbs in patients with CBD, the left hemisphere contained the
bulk of the local metabolic reductions that constitute this disease
topography. The expression of the left hemi-CBDRP was separ-
ately computed in the two hemispheres of each subject (see
‘Materials and methods’ section). The left-right difference in
these values was used to compute a CBDRP asymmetry index
for each subject. Relative to the normal control group (NLNS),
the asymmetry index was greater in the CBD (CBDNS:
P5 0.001; CBDFR: P5 0.001; Mann-Whitney tests) and the PSP
(PSPNS: P50.005; PSPFR: P = 0.005; Mann-Whitney tests) sam-
ples. However, unlike the original whole-brain pattern, the CBDRP
asymmetry index (Fig. 3A) was significantly greater in CBD relative
to PSP in both differential diagnosis sets (P40.003 for CBDNS
versus PSPNS and CBDFR versus PSPFR).
We also computed PSPRP expression in each of these subjects.
PSPRP scores were indeed elevated in both PSP groups
(P5 0.001; Mann-Whitney tests for PSPNS versus NLNS and
PSPFR versus NLNS), and also in the two CBD samples
(P5 0.005 for CBDNS versus NLNS; P = 0.07 for CBDFR versus
NLNS). Moreover, PSPRP expression was significantly higher in
PSPNS compared to CBDNS (Fig. 3B, left; P50.01), but was not
different for the PSPFR and CBDFR groups (Fig. 3B, right; P = 0.27).
Indeed, voxel-wise correlation of CBDRP and PSPRP revealed
moderate overlap between the two patterns (R2 = 0.24,
P50.001). There was also a significant correlation between ex-
pression of CBDRP and PSPRP in individual subjects with CBD
(Spearman’s r = 0.58, P = 0.001, n = 27; combined group of
CBDNS, CBDGR and CBDFR) or PSP (Spearman’s r = 0.57,
P50.001, n = 51; combined group of PSPNS and PSPFR). These
findings suggest that, singly, the two whole-brain network meas-
ures are insufficient for prospective discrimination between the
two diseases. That said, adequate differentiation between these
conditions may be possible using multiple network measures in
combination.
Automated algorithm for differential
diagnosis of corticobasal degeneration
versus progressive supranuclear palsy
For accurate differential diagnosis of CBD and PSP, we next em-
ployed a logistic classification algorithm to determine whether the
three network measures (the whole-brain CBDRP expression, the
CBDRP asymmetry index, and the whole-brain PSPRP expression),
individually or in combination, provided accurate discrimination
between clinically diagnosed CBD and PSP patients at the single
case level. In the training sample comprised of the 10 CBDNS and
the 10 age-matched PSPNS cases (Fig. 4A), a logistic regression
model based on the CBDRP asymmetry index and whole-brain
PSPRP expression values produced better group separation
(2 = 15.6, P = 0.0004; likelihood ratio test) than any individual
univariate model as well as the other multivariate models.
Receiver-operating characteristic (ROC) analysis of this selected
bivariate model revealed that the area under-the-curve (AUC)
was 0.94 (P50.0001), indicating excellent differentiation be-
tween the CBD and PSP patients. Odds ratio estimates for this
model were 1.84 [95% confidence interval (CI) = 1.06–3.20,
P = 0.03] for CBDRP asymmetry and 0.42 (95% CI = 0.15–1.19,
P = 0.10) for PSPRP expression. Thus, greater asymmetry occur-
ring in concert with lower PSPRP expression suggests a higher
likelihood of CBD relative to PSP in a given subject.
To validate this algorithm, we applied the discriminant function
of the model prospectively to individual subjects in an independ-
ent testing set of 17 CBD (CBDGR + CBDFR) and 41 PSP
(PSPNS + PSPFR) subjects (Fig. 4B). The classification probabilities
of CBD and PSP in each case were computed using the algorithm
with the individual CBDRP asymmetry index and the whole-brain
PSPRP expression value for that individual. The probabilities of
all subjects were illustrated in a frequency distribution diagram
Figure 3 CBDRP asymmetry index and PSPRP expression.
(A) The CBDRP asymmetry index was found to be greater in
both CBD patient cohorts (CBDNS versus PSPNS: P50.002;
CBDFR versus PSPFR: P50.003; Mann-Whitney tests) than for
the respective PSP patient cohorts. (B) Expression of a previously
identified PSP-related pattern (PSPRP) (Eckert et al., 2008) was
significantly higher in the PSPNS group relative to the CBDNS
group (P50.01; Mann-Whitney test), but was not different
between the PSPFR and CBDFR groups (P = 0.27). Error bars
represent SE.
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(Fig. 5A). The subjects with higher CBD probabilities clustered on
the right and those with higher PSP probabilities clustered on the
left. ROC curve analysis (Fig. 5B) further revealed an AUC of 0.92
(P50.0001) indicating a high accuracy for the correct classifica-
tion of CBD and PSP subjects. Based on these curves, the optimum
cut-off probability for classifying CBD was 0.78 and for PSP was
0.63. Thus, patients whose probability values for CBD were 40.78
were classified as CBD and those whose probability values for PSP
were 40.63 as PSP; patients whose probability values for CBD
and PSP were both lower than their corresponding cut-off values
were classified as indeterminate.
The image-based classification for each testing subject was com-
pared to the ultimate clinical diagnosis of that individual. For the
subjects diagnosed clinically with CBD, the image-based classifica-
tions had sensitivity of 76.5% (13/17, number of subjects), spe-
cificity of 92.7% (38/41), positive predictive value of 81.3% (13/
16), and negative predictive value of 90.5% (38/42). For the PSP
patients, the imaging classifications had 78.0% (32/41) sensitivity,
94.1% (16/17) specificity, 97.0% (32/33) positive predictive
value, and 64.0% (16/25) negative predictive value. Nine of 58
testing subjects (15.5%) were classified as indeterminate by com-
parison of their probability values with the corresponding cut-offs.
Of these, six were ultimately diagnosed as having PSP and three
as CBD.
Discussion
In this study, we describe and validate a specific metabolic covari-
ance pattern associated with CBD, termed CBDRP. Expression of
this pattern reliably differentiated patients with clinical CBD from
healthy control subjects in two independent samples. The CBDRP
metabolic topography characterized by asymmetrical reductions
(worse in the left hemisphere, i.e. contralateral to the more af-
fected body side) in the cerebrum, lateral parietal and frontal re-
gions and thalamus, with relative bilateral increases in occipital
regions. This abnormal spatial covariance topography is consistent
with previously reported metabolic (Eidelberg et al., 1991; Eckert
et al., 2005; Teune et al., 2010; Hellwig et al., 2012; Zhao et al.,
2012) and structural (Soliveri et al., 1999; Boxer et al., 2006;
Erbetta et al., 2009) imaging changes in CBD identified using
simple region-level analytical methods. Indeed, the pattern reflects
the often marked asymmetry that is characteristic of the clinical
presentation of CBD (Poston, 2010).
We acknowledge that derivation of a disease-specific pattern
has to rely on the accuracy of the clinical diagnosis. This may be
particularly problematic in CBD, where patients with the clinical
diagnosis of CBD may be found to have another underlying path-
ology on post-mortem examination, mainly PSP, but including
Alzheimer’s disease, vascular parkinsonism, and Pick’s disease
(Litvan et al., 1997; Josephs et al., 2006; Hu et al., 2009). This
has prompted some investigators to propose the term corticobasal
syndrome to describe the clinical findings in living patients, while
reserving CBD for the definitive diagnosis made at post-mortem.
That said, to derive and validate a metabolic pattern that is highly
specific to CBD, we only included probable CBD patients who had
parkinsonism with limb asymmetry and apraxia on clinical exam-
ination, without extraocular movement abnormalities (Litvan
et al., 1997). Thus, it is likely that the majority of the patients
in our cohorts did indeed have CBD, as was confirmed by post-
mortem examination of the brains of three of the patients whose
scans were used to derive the CBDRP metabolic topography.
Figure 4 CBDRP asymmetry index and PSPRP expression in individual CBD and PSP patients. (A) Using logistic regression analysis, we
found that a discriminant function using CBDRP asymmetry index and PSPRP expression resulted in the best differentiation between
CBDNS and PSPNS (
2 = 15.6, P = 0.0004; likelihood ratio test) (see text). Scatter plot displays the CBDRP asymmetry index and PSPRP
expression in the training sample of 10 patients with CBD and 10 age-matched patients with PSP. (B) The automated algorithm for
differential diagnosis was prospectively validated on a case-by-case basis in a testing sample of 58 patients, including 17 patients with CBD
and 41 patients with PSP (see text). Scatter plot displays the CBDRP asymmetry index and PSPRP expression for these patients. In both
plots, CBD and PSP patients are indicated by blue and orange circles, respectively.
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The clinical presentation of CBD may be quite heterogeneous.
Indeed, the specific CBDRP topography described in this study
may not be a consistent feature of variant phenotypes of the
disorder, such as those with early dementia, which can be con-
fused with Alzheimer’s disease (Alexander et al., 2014). Validation
of this pattern as a specific diagnostic tool for CBD will ultimately
be dependent on the accrual of additional cases with pathological
confirmation. A separate possible problem is the low sensitivity in
the diagnosis, a situation where neuroimaging could potentially be
of benefit. It is well recognized that patients with the pathological
diagnosis of CBD frequently may have different clinical syndromes
and the true diagnosis is missed, as can occur in individuals diag-
nosed clinically as having PSP, Alzheimer’s disease, progressive
aphasia, symmetrical parkinsonism, or frontotemporal dementia
(Litvan et al., 1997; Hu et al., 2009; Boeve, 2011; Hassan
et al., 2011). To assess the use of CBDRP expression in this con-
text, it will be necessary to identify patients with pathologically
confirmed CBD but with a different clinical diagnosis – and who
had also undergone metabolic imaging in life.
In our cohorts, CBDRP expression was abnormally elevated in
established CBD patients compared with healthy control subjects.
Interestingly, one patient did undergo imaging twice. At the first
time point, the clinical diagnosis was one of focal dystonia, with-
out other features of CBD. CBDRP expression at the time was
mildly elevated, only to become significantly elevated 3 years
later, when the clinical diagnosis was established. We have previ-
ously shown that in Parkinson’s disease, expression of motor- and
cognition-related patterns (PDRP and PDCP, respectively) increase
in individual patients over time (Huang et al., 2007; Tang et al.,
2010a). Indeed, expression of PDCP is within the normal range
Figure 5 Results of the automated algorithm for differential diagnosis between CBD and PSP. (A) Frequency distribution diagram
illustrating the disease probabilities of CBD and PSP calculated for the 58 subjects (17 CBD and 41 PSP) in the testing sample. Individual
patients were classified as having CBD if the probability value for CBD (PCBD) was40.78 (i.e. cut-offCBD; 16 subjects located to the right of
the right dotted line), and as PSP if the probability value for PSP (PPSP) was 40.63 (i.e. cut-offPSP; 33 subjects located to left of the left
dotted line). Patients whose probability values for CBD and PSP were both lower than their corresponding cut-off probabilities were
classified as indeterminate cases, i.e. nine subjects located between the left and right dotted lines. The final clinical diagnoses of CBD and
PSP patients are indicated by blue and orange bars, respectively. (B) Based on the receiver-operating characteristic (ROC) analysis for all
patients in the testing sample, the area-under-the-curve (AUC) for PSP (left) and CBD (right) was 0.92 (P50.0001), consistent with that
(0.94, P5 0.0001; not shown) of the training sample. The cut-off probability of each disease was determined based on the inflection point
(asterisk) on each curve corresponding to the high specificity and sensitivity for classifying individual patients with each disease.
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early in the disease course (Tang et al., 2010a). Our finding in this
one patient, coupled with a similar report in two patients with
MSA (Poston et al., 2012), suggests that disease-specific patterns
may be useful markers of disease progression in individual patients
in all forms of neurodegenerative parkinsonism. Nevertheless, lon-
gitudinal studies will be required to confirm this finding. Given the
clinical uncertainty early in the disease process, it will be of special
interest to define the earliest point at which abnormal pattern
expression can reliably aid in the diagnosis of these disorders.
Expression values for CBDRP were not abnormally elevated in
two MSA cohorts. However, while abnormal in the three CBD
cohorts that we studied, these values were also elevated in PSP.
Expression values for the previously characterized PSPRP (Eckert
et al., 2008; Tang et al., 2010b) likewise are elevated in inde-
pendent populations of both CBD and PSP. Moreover, CBDRP and
PSPRP expression correlated in individual patients. While CBD and
PSP are clinically and pathologically thought to be distinct, both
are classified as tauopathies and share deposition of four repeat
tau. This contrasts with the mixture of three repeat and four
repeat isoforms seen in Alzheimer’s disease, suggesting perhaps
a shared pathogenesis for the two disorders (Dickson, 1999;
Boeve et al., 2003). It is intriguing to speculate that abnormally
elevated expression of both patterns in PSP and CBD is also a
consequence of regional overlap in their respective neuropatho-
logical landscapes. A significant portion of patients with clinical
PSP are found to have CBD pathology and vice versa (Josephs
et al., 2006; Murray et al., 2007; Ling et al., 2010). Indeed, the
correlation between the two patterns, in terms of both spatial
topography and subject expression, suggests that the current find-
ing is not simply one of missed diagnoses. Rather, there is true
regional overlap between their metabolic profiles.
In addition, despite different pathologies, recent studies have
suggested that Alzheimer’s disease is a common clinical mimic of
CBD (Alexander et al., 2014). Patients with Alzheimer’s disease
have similar cognitive deficits to CBD, with less rigidity and dys-
tonia (Hu et al., 2009; Hassan et al., 2011). Thus, we performed a
preliminary analysis of CBDRP expression in Alzheimer’s disease
patients, showing that this pattern is not abnormally expressed
in these patients relative to healthy controls (personal communi-
cation). Indeed, a prior study has demonstrated that the metabolic
deficits in Alzheimer’s disease tend to involve cortical regions
(Habeck et al., 2008) that are rather distinct from those that
define the CBDRP topography. Nonetheless, because non-demen-
ted subjects exclusively were used to identify and validate the
CBDRP topography, it is not clear whether this pattern can effect-
ively differentiate patients with CBD from clinical ‘look alike’ syn-
dromes with underlying Alzheimer pathology. Further investigation
is needed to determine the accuracy of network-based classifica-
tion in CBD and in clinical mimics of this disorder.
Taking advantage of the clinical asymmetry of CBD, which is a
distinctive feature of the disease and its metabolic topography, we
measured the degree of hemispheric asymmetry that was present
at the network level in the individual subjects. We reasoned that
this measure would be more specific in differentiating CBD from
the more symmetrical metabolic profile of PSP. Indeed, hemi-
spheric asymmetry for CBDRP expression separated the CBD and
PSP groups with greater accuracy than whole-brain CBDRP
expression. Ultimately, the classification algorithm based on
CBDRP asymmetry index and whole-brain PSPRP expression ac-
curately discriminated between CBD and PSP subjects in whom
the precise clinical diagnosis was uncertain at the time they
were referred for the imaging study. Classifications of these indi-
viduals based upon these imaging measures accorded well with
final clinical diagnoses reached independently by movement dis-
order specialists at clinical follow-up (Tang et al., 2010b; Teune
et al., 2010; Hellwig et al., 2012). As a result, high specificity and
positive predictive value were achieved for image-based classifica-
tion of CBD on an individual case basis, with all three pathologic-
ally confirmed PSP cases classified as non-CBD. These findings
provide strong support for the specificity of the CBDRP network
and the validity of the classification algorithm that we have iden-
tified in this study.
The accuracy of prediction using this automated approach is in
line with previously reported values using trained readers (Eckert
et al., 2005; Hellwig et al., 2012), but does not require visual
judgement whether trained or not. We have previously described
an automated algorithm that can differentiate Parkinson’s disease
from atypical parkinsonian syndromes (excluding CBD), and fur-
ther subdivide atypical parkinsonian syndromes into MSA and PSP
(Tang et al., 2010b; Niethammer and Eidelberg, 2012; Tripathi
et al., 2012). With the data presented in the present study, we
aim to refine this algorithm to include CBD, thereby improving the
accuracy of diagnosis in clinically ambiguous cases. We recognize,
however, given the protean clinical presentation of CBD, blinded,
prospective imaging studies involving larger validation samples and
longitudinal network measurements, ideally with post-mortem
confirmation, will be necessary to establish the use of CBDRP to
assist in diagnosis and for screening potential participants in clinical
trials.
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